Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments

A compound of the formula I,

• wherein
• R1 is H, (C1–C10)-alkyl, (C3–C10)-cycloalkyl, (C2–C6)-alkenyl, (C2–C6)-alkynyl, (C6–C10)-aryl or heterocyclyl,
• wherein said (C1–C10)-alkyl, (C3–C10)-cycloalkyl, (C2–C6)-alkenyl, (C2–C6)-alkynyl, (C6–C10)-aryl and heterocyclyl radicals are optionally substituted one or more times by F, Cl, Br, I, CN, NO2, OH, —CF3, (C1–C6)-alkyl, (C2–C6)-alkenyl, (C2–C6)-alkynyl, OR3, NR3R4, COR3, CO2R3, CONR3R4, (C1–C6)-alkylene-OR3, (C1–C6)-alkylene-NR3R4, (C1–C6)-alkylene-SR3, alkylene-SOR3, alkylene-SO2R3, (C1–C6)-alkylene-COR3, (C1–C6)-alkylene-COOR3, (C1–C6)-alkylene-CONR3R4, (C1–C6)-alkylene-O—P(O)(OR3)2, SR3, SOR3, SO2NR3R4, SO2R3, (C1–C6)-alkylene-(C3–C10)-cycloalkyl, (C1–C6)-alkylene-(C6–C10)-aryl, (C1–C6)-alkylene-heterocyclyl, (C3–C10)-cycloalkyl, (C6–C10)-aryl or heterocyclyl,
• wherein said (C6–C10)-aryl is optionally substituted one or more times by F, Cl, Br, I, CN, NO2, OH, —CF3, (C1–C6)-alkyl, (C2–C6)-alkenyl, (C2–C6)-alkynyl, OR3, NR3R4, COR3, CO2R3 or CONR3R4,
• and wherein said heterocyclyl is optionally substituted one or more times by F, Cl, Br, I, CN, NO2, OH, —CF3, (C1–C6)-alkyl, OR3, NR3R4, COR3, CO2R3 or CONR3R4;
• R2 is H, (C1–C10)-alkyl, (C3–C10)-cycloalkyl, (C2–C6)-alkenyl, (C2–C6)-alkynyl, (C6–C10)-aryl, heterocyclyl, COR3, COOR3, CONR3R4 or CN,
• wherein said (C1–C10)-alkyl, (C3–C10)-cycloalkyl, (C2–C6)-alkenyl, (C2–C6)-alkynyl, (C6–C10)-aryl and heterocyclyl radicals are optionally substituted one or more times by F, Cl, Br, I, CN, NO2, SH, SF5, OH, (C1–C6)-alkyl, —CF3, (C2–C6)-alkenyl, (C2–C6)-alkynyl, OR3, OP(O)(OR3)2, NR3R4, NR3CONR3R4, COR3, OCOR3, OCOOR3, COOR3, CONR3R4, OCONR3R4, (C1–C6)-alkylene-OR3, (C1–C6)-alkylene-NR3R4, (C1–C6)-alkylene-NR3SO2R4, (C1–C6)-alkylene-SR3, alkylene-S(O)R3, alkylene-S(O)2R3, alkylene-S(O)2NR3R4, (C1–C6)-alkylene-COR3, (C1–C6)-alkylene-COOR3, (C1–C6)-alkylene-CONR3R4, SR3, SOR3, SO2R3, SO2NR3R4, NR3SO2R4, (C1–C6)-alkylene-(C3–C10)-cycloalkyl, (C1–C6)-alkylene-(C6–C10)-aryl, (C1–C6)-alkylene-heterocyclyl, (C3–C10)-cycloalkyl, (C6–C10)-aryl or heterocyclyl;
• R3, R4 are each, independently of one another, H, (C1–C6)-alkyl, —CF3, (C3–C10)-cycloalkyl, (C6–C10)-aryl, heterocyclyl, (C1–C6)-alkylene-CONR5R6, CONR5R6, (C1–C6)-alkylene-COOR5, COOR5, COR5, (C1–C6)-alkylene-COR5, (C1–C6)-alkylene-OR5, (C1–C6)-alkylene-NR5R6, (C1–C6)-alkylene-SR5, (C1–C6)-alkylene-S(O)R5, (C1–C6)-alkylenee-S(O)2R5, S(O)R5, S(O)2R5, (C1–C4)-alkylene-(C6–C10)-aryl or (C1–C4)-alkylene-heterocyclyl;
• R5, R6 are each, independently of one another, H, (C1–C6)-alkyl, (C1–C6)-alkylene-(C6–C10)-aryl, —(C6–C10)-aryl, heterocyclyl or (C1–C6)-alkylene-heterocyclyl;
• X is S, SO or SO2;
• and pharmaceutically acceptable salts thereof.